Practical reading from Professor Paul Lee and the Lincolnshire Hip Clinic team — across hip replacement, Arthrosamid, ChondroFiller, PRP and the wider world of hip and groin pain.
A ChondroFiller hip injection costs £6,500–£9,500 in the UK. The collagen scaffold triggers the patient's progenitor cells to regenerate cartilage in the focal defect—a cellular mechanism that distinguishes it from standard steroid and lubrication injections and accounts for its higher cost.
Hip cartilage has no blood supply and cannot repair itself once damaged to exposed bone. Two injectable treatments — ChondroFiller gel and autologous stem cells — aim to trigger biological repair for focal defects, but address different disease stages and carry asymmetric evidence burdens in current hip practice.
Hip cartilage is avascular and cannot self-repair. ChondroFiller injects a collagen scaffold that the body's own progenitor cells migrate into, using it to build fibrocartilage-like repair tissue that develops progressively over three to six months.
ChondroFiller is an injectable collagen scaffold that gels within minutes, supporting the patient's own cartilage repair; 70–85% achieve meaningful relief from hip pain and stiffness within three to five years.
A torn hip labrum breaks the seal around the joint; poor blood supply hampers healing, uneven pressure accelerates cartilage wear, and osteoarthritis develops prematurely.
Hyaline cartilage on the femoral head lacks blood vessels and repair cells, so focal defects do not heal with rest and will progress reliably to osteoarthritis. Osteochondral autograft transfer addresses this by transplanting healthy cartilage-bone plugs from low-load zones of the same femoral head into the defect.
ChondroFiller, a Class III collagen scaffold injected into the hip, gels in situ and prompts endogenous repair by recruiting the patient's progenitor cells; it works only for focal cartilage lesions, not generalised joint wear.
Structured physiotherapy for FAI produces equivalent pain and functional outcomes to hip arthroscopy in a 2025 meta-analysis of 21 trials; 70–82% of patients avoid surgery at two-year follow-up.
Hip cartilage damage extending more than halfway through the layer or exposing bone (ICRS Grade III–IV) qualifies for ChondroFiller when isolated under 6 cm² and surrounded by healthy cartilage (Tönnis Grade 0–1).
Lincolnshire Hip Clinic
Led by Professor Paul Lee
Start with a free, non-medical discovery call with our team. We will tell you, honestly, which of our pathways — surgical or non-surgical — fits your situation. No GP referral, no pressure to proceed.
What we offer
